– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a compa ...

Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases, with a commitment to improving patient lives [2][3] Company Overview - EyePoint is a clinical-stage biopharmaceutical company utilizing its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [2] - The lead product candidate, DURAVYU, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 trials for wet age-related macular degeneration (wet AMD) and has completed Phase 2 trials for diabetic macular edema (DME) [2][4] - The company anticipates discussions with regulatory agencies in Q2 2025 regarding pivotal program plans based on positive Phase 2 results from the VERONA trial in DME [2] Pipeline Programs - Additional pipeline programs include EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E to potentially enhance outcomes in serious retinal diseases [3] - Durasert technology has been safely administered to thousands of patient eyes across four FDA-approved products for various disease indications [3] Upcoming Investor Conferences - EyePoint management will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 12, 2025 [5]

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register ...

– Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME – WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. ...

EyePoint Pharmaceuticals (EYPT) Update / Briefing February 05, 2025 08:00 AM ET Company Participants Jay Duker - President & CEORamiro Ribeiro - Chief Medical OfficerYigal Nochomovitz - DirectorKambiz Yazdi - Vice President - Equity ResearchGraig Suvannavejh - Managing Director Conference Call Participants Tessa Romero - Equity AnalystTyler Van Buren - Managing Director, Senior Biotech Equity Research AnalystYatin Suneja - Biotechnology Research AnalystJennifer Kim - AnalystColleen Kusy - Senior Research An ...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1][2] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET. A webcast and subsequent archived replay of the fir ...

– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors – – Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – – Presenting at the 43rd Annual J.P. Morgan Healthcare ...